



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

December 2, 2015

**Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa 50265**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) DHS Recommendation Letter – October 2015
3. IME Pharmacy Update
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
 - a) Duplicate Benzodiazepines – Follow Up
 - b) Niacin plus Statin – Follow Up
 - c) Duplicate Antipsychotics in Children – Follow Up
 - d) Duplicate Antipsychotics in Adults – Follow Up
 - e) Methadone Utilization – Initial Review
8. ProDUR Edits
 - a) Tramadol Utilization in Members Under 18 Years of Age
9. Public Comment (See Conflict of Interest Disclosure Form)
10. Prior Authorization
 - a) PCSK9 Inhibitors – Initial Review - Updated
 - b) Valsartan/Sacubitril (Entresto™) – Initial Review

- c) Adalimumab (Humira®) for Hidradenitis Suppurativa – Initial Review
- d) Sodium Oxybate (Xyrem®) – Initial Review
- e) Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents – Initial Review
- f) Non-Parenteral Vasopressin Derivatives of Posterior Pituitary Hormone Products – Initial Review - Removal of PA for Nocturnal Enuresis
- g) Growth Hormone – Second Review
- h) Cholic Acid (Cholbam®) – Second Review
- i) Binge Eating Disorder Agents – Second Review

11. Miscellaneous

- a) DUR Digest Vol. 28, No. 2 – Initial Review
- b) MedWatch

12. Executive Closed Session

- a) Approval of Minutes
- b) Unique Member Profile(s)

13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting February 3, 2016***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA 50265**